MilliporeSigma partners with Baylor College of Medicine to advance vaccine manufacturing platform to fight COVID-19.
M2 PHARMA-May 28, 2020-MilliporeSigma partners with Baylor College of Medicine to advance vaccine manufacturing platform to fight COVID-19
(C)2020 M2 COMMUNICATIONS
Life science company MilliporeSigma said on Wednesday that it has extended its ongoing collaboration with Baylor College of Medicine to advance a manufacturing platform to develop a safe and effective COVID-19 vaccine and transition to Phase 1 clinical trials.
Using key learnings from their ongoing collaboration on a schistosomiasis vaccine, MilliporeSigma, along with researchers at Baylor College of Medicine and the Texas Children's Hospital Center for Vaccine Development, is optimising the production process to advance two COVID-19 vaccine candidates, including the CoV RBD219-N1 vaccine candidate expected to enter clinical trials later this year.
As part of the agreement, MilliporeSigma will help to accelerate their suitability for large-scale manufacturing. The collaboration will focus on improvements to production efficiency, yield, robustness, scalability and costs. The goal for the partnership is to develop a suitable manufacturing process and steps that would lead to a scale-up approach suitable for pilot and later industrial production.
Additionally, the partners will develop a new manufacturing platform for a second COVID-19 vaccine candidate to shorten the time to enter into Phase 1 clinical trials.
MilliporeSigma is the life science business of Merck KGaA (ETR:MRK).
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||May 28, 2020|
|Previous Article:||Athletico offers COVID-19 Recovery and Rehabilitation service.|
|Next Article:||Maersk Drilling's Q1 2020 results affected by COVID-19 pandemic and falling oil prices.|